Geert D'Haens MD, PhD, AGAF

A conclusion emphasizing the importance of translating clinical research into everyday practice and continuing innovation to improve patient quality of life and long-term outcomes.

Combination Therapies for IBD and Future Outlook

The Peers & Perspectives series episode on Optimizing Therapeutic Strategies in Inflammatory Bowel Disease opens with a discussion on redefining remission. Traditional endpoints, such as symptom improvement, are increasingly being supplemented with objective measures like endoscopic and histologic healing to better capture treatment effectiveness. The conversation highlights how deeper healing correlates with sustained remission and improved quality of life, while also addressing the practical challenges of implementing these advanced endpoints in clinical practice—balancing diagnostic precision, resource availability, and patient accessibility.

Building on this foundation, the program transitions to an analysis of early intervention strategies and their impact on disease trajectory. Recent research underscores that initiating advanced therapy earlier in the disease course can significantly enhance both short- and long-term outcomes. The discussion delves into the importance of identifying high-risk individuals before the onset of severe symptoms and tailoring therapy based on disease phenotype, risk profile, and treatment goals. Comparisons are drawn between established and emerging agents—including biologics, JAK inhibitors, S1P receptor modulators, and IL-23 inhibitors—to help clinicians navigate evolving treatment algorithms with confidence.

In its closing section, the program looks ahead to the future of IBD management, focusing on the role of predictive medicine and the integration of novel biomarkers, genetic insights, and multi-omics data. These tools are expected to transform how clinicians diagnose, stratify, and monitor patients—enabling more personalized, preventative, and data-driven approaches to care. The discussion concludes with a forward-looking perspective on clinical research priorities, emphasizing the need for continued innovation in treatment endpoints, combination therapy trials, and patient-centered outcome measures that define the next generation of IBD care.

Videos

Forward-looking perspectives on how predictive biomarkers, genetic profiling, and precision tools will guide individualized IBD management in the coming years.

Role of IL-12/IL-23 Inhibitors in the Treatment Landscape of IBD

Exploration of combination and sequencing strategies for patients with refractory or advanced disease to achieve comprehensive disease control.

Application of S1P Receptor Agonists for Treating IBD

alysis of how to balance established therapies such as anti-TNFs and immunomodulators with novel agents like JAK inhibitors, S1P modulators, and IL-23 inhibitors.

Available Therapy Options for IBD and Their Place in the Current Treatment Setting

Analysis of how to balance established therapies such as anti-TNFs and immunomodulators with novel agents like JAK inhibitors, S1P modulators, and IL-23 inhibitors.

Geert D'Haens MD, PhD, AGAF

Articles